Bin Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bin Liang has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Yunhui Li
Department of Vascular Surgery, Jinan People's Hospital Affiliated to Shandong First Medical University, China
4 shared publications Jianying Zhao
Department of Clinical Laboratory, No. 202 Hospital of PLA, Shenyang, China
3 shared publicationsYunhui Li
Department of Laboratory Medical Center, General Hospital of Northern Theater Command, Shenyang, China
3 shared publicationsTianjiao Wang
Department of Bioinformatics, Key laboratory of Cell Biology, Ministry of Public Health, and Key Laboratory of Medical Cell Biology, Ministry of Education, School of Life Sciences, China Medical University, China
2 shared publications- Tianjiao Wang
Bioinformatics Department, Key Laboratory of Cell Biology, Ministry of Public Health & Key Laboratory of Medical Cell Biology, Ministry of Education, School of Life Sciences, China Medical University, Shenyang 110122, China
2 shared publications Xuan Wang
Graduate School, Dalian Medical University, Dalian, China
2 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1589760
Global trends of early-onset Parkinson’s disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021
Background: This study aims to evaluate the global, regional, and national trends in prevalence, incidence, mortality, and DALYs for early-onset Parkinson’s disease (EOPD) from 1990 to 2021.Methods: All data from the Global Burden of Diseases (GBD) 2021 were stratified by age, sex, location, and socio-demographic index (SDI). We performed comprehensive analysis to reveal trends for EOPD, utilizing average annual percentage change (AAPC), joinpoint regression analysis, health inequality analysis, frontier analysis, and Bayesian age-period-cohort (BAPC) models.Results: In 2021, the global case numbers of prevalence, incidence, mortality, and DALYs for EOPD were 483872.47 (95% UI: 328861.91–682509.05), 81046.67 (95% UI: 48161.87–122328.00), 2245.68 (95% UI: 1995.24–2495.67), and 180325.32 (95% UI: 145990.30–225031.04). The age-standardized prevalence rate (ASPR), age-standardized incidence rate (ASIR), and age-standardized DALYs rate (ASDR) keep increasing from 1990 to 2021, and the age-standardized death rate (ASMR) occurred the decline trend. Male showed higher ASPR, ASIR, ASMR, and ASDR across all age groups. The geographical disparities at regional and national level were evident. Significant disparities in EOPD burden by SDI were observed, exhibiting a worsening inequality over time. The frontier analysis lists some countries and territories requiring urgent action to mitigate EOPD burden. Furthermore, it was anticipated that the ASPR and ASIR would consistently increase during 2021 to 2030, while the ASMR and ASDR would decrease.Conclusion: EOPD demonstrated notable heterogeneity across age, gender, and geography. The increasing burden of EOPD underscored the urgent need for targeted public health strategies and policies, especially in undeveloped regions.
- 1 August 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1589760
Open AccessGlobal trends of early-onset Parkinson’s disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021
Background: This study aims to evaluate the global, regional, and national trends in prevalence, incidence, mortality, and DALYs for early-onset Parkinson’s disease (EOPD) from 1990 to 2021.Methods: All data from the Global Burden of Diseases (GBD) 2021 were stratified by age, sex, location, and socio-demographic index (SDI). We performed comprehensive analysis to reveal trends for EOPD, utilizing average annual percentage change (AAPC), joinpoint regression analysis, health inequality analysis, frontier analysis, and Bayesian age-period-cohort (BAPC) models.Results: In 2021, the global case numbers of prevalence, incidence, mortality, and DALYs for EOPD were 483872.47 (95% UI: 328861.91–682509.05), 81046.67 (95% UI: 48161.87–122328.00), 2245.68 (95% UI: 1995.24–2495.67), and 180325.32 (95% UI: 145990.30–225031.04). The age-standardized prevalence rate (ASPR), age-standardized incidence rate (ASIR), and age-standardized DALYs rate (ASDR) keep increasing from 1990 to 2021, and the age-standardized death rate (ASMR) occurred the decline trend. Male showed higher ASPR, ASIR, ASMR, and ASDR across all age groups. The geographical disparities at regional and national level were evident. Significant disparities in EOPD burden by SDI were observed, exhibiting a worsening inequality over time. The frontier analysis lists some countries and territories requiring urgent action to mitigate EOPD burden. Furthermore, it was anticipated that the ASPR and ASIR would consistently increase during 2021 to 2030, while the ASMR and ASDR would decrease.Conclusion: EOPD demonstrated notable heterogeneity across age, gender, and geography. The increasing burden of EOPD underscored the urgent need for targeted public health strategies and policies, especially in undeveloped regions.
- Open Access
- 11 October 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1263389
Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation
Objective: Recently, circulating donor-derive cell free DNA (dd-cfDNA) has gained growing attention in the field of solid organ transplantation. The aim of the study was to analyze circulating dd-cfDNA levels in graft rejection, ACR and AMR separately for each rejection type compared with non-rejection, and assessed the diagnostic potential of dd-cfDNA levels in predicting graft rejection after lung transplantation.Methods: A systematic search for relevant articles was conducted on Medline, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases without restriction of languages. The search date ended on June 1, 2023. STATA software was used to analyze the difference between graft rejection, ACR, AMR and stable controls, and evaluate the diagnostic performance of circulating dd-cfDNA in detecting graft rejection.Results: The results indicated that circulating dd-cfDNA levels in graft rejection, ACR, and AMR were significantly higher than non-rejection (graft rejection: SMD=1.78, 95% CI: 1.31-2.25, I2 = 88.6%, P< 0.001; ACR: SMD=1.03, 95% CI: 0.47-1.59, I2 = 89.0%, P < 0.001; AMR: SMD= 1.78, 95% CI: 1.20-2.35, I2 = 89.8%, P < 0.001). Circulating dd-cfDNA levels distinguished graft rejection from non-rejection with a pooled sensitivity of 0.87 (95% CI: 0.80-0.92) and a pooled specificity of 0.82 (95% CI: 0.76-0.86). The corresponding SROC yield an AUROC of 0.90 (95% CI: 0.87-0.93).Conclusion: Circulating dd-cfDNA could be used as a non-invasive biomarker to distinguish the patients with graft rejection from normal stable controls.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42023440467.
- 11 October 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1263389
Open AccessCirculating donor-derived cell-free DNA as a marker for rejection after lung transplantation
Objective: Recently, circulating donor-derive cell free DNA (dd-cfDNA) has gained growing attention in the field of solid organ transplantation. The aim of the study was to analyze circulating dd-cfDNA levels in graft rejection, ACR and AMR separately for each rejection type compared with non-rejection, and assessed the diagnostic potential of dd-cfDNA levels in predicting graft rejection after lung transplantation.Methods: A systematic search for relevant articles was conducted on Medline, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases without restriction of languages. The search date ended on June 1, 2023. STATA software was used to analyze the difference between graft rejection, ACR, AMR and stable controls, and evaluate the diagnostic performance of circulating dd-cfDNA in detecting graft rejection.Results: The results indicated that circulating dd-cfDNA levels in graft rejection, ACR, and AMR were significantly higher than non-rejection (graft rejection: SMD=1.78, 95% CI: 1.31-2.25, I2 = 88.6%, P< 0.001; ACR: SMD=1.03, 95% CI: 0.47-1.59, I2 = 89.0%, P < 0.001; AMR: SMD= 1.78, 95% CI: 1.20-2.35, I2 = 89.8%, P < 0.001). Circulating dd-cfDNA levels distinguished graft rejection from non-rejection with a pooled sensitivity of 0.87 (95% CI: 0.80-0.92) and a pooled specificity of 0.82 (95% CI: 0.76-0.86). The corresponding SROC yield an AUROC of 0.90 (95% CI: 0.87-0.93).Conclusion: Circulating dd-cfDNA could be used as a non-invasive biomarker to distinguish the patients with graft rejection from normal stable controls.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42023440467.
- Open Access
- 12 August 2022
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 9, 982032
Circulating trace elements status in COVID-19 disease: A meta-analysis
Trace elements are a group of essential metals or metalloids, which are necessary for life, and present in minute amounts. Despite substantial researches highlighting the importance of trace elements in Coronavirus disease 2019 (COVID-19) diseases, a thorough evaluation of the levels of circulating trace elements is lacking. Therefore, we conducted a systematic review and meta-analysis to evaluate the trace element status (Zn, Fe, Cu, Mg, and Se) in COVID-19 disease. We also assessed the relationship between circulating trace elements and COVID-19 disease severity and survival status during follow-up. We searched comprehensively MEDLINE, Web of Science, CNKI, and WangFang databases without language restriction, between November 1, 2019 and April 1, 2022. The search identified 1,566 preliminary references. A total of 49 studies met the eligibility criteria and were included in the review, and 42 studies were included in the final meta-analysis. Meta-analysis showed that COVID-19 patients had significantly lower circulating Zn (SMD: −0.83, 95% CI: −1.19 to −0.46, P < 0.001), Fe (SMD: −1.56, 95% CI: −2.90 to −0.21, P = 0.023), and Se (SMD: −0.75, 95% CI: −0.94 to −0.56, P < 0.001) levels than healthy controls, and circulating Zn (SMD: −0.47, 95% CI: −0.75 to −0.18, P = 0.002), Fe (SMD: −0.45, 95% CI: −0.79 to −0.12, P = 0.008), and Se (SMD: −0.27, 95% CI: −0.49 to −0.04, P = 0.020) levels were associated with the presence of severity status in COVID-19 patients. Moreover, circulating Fe levels in non-survivors were significantly lower than survivors in COVID-19 (SMD: −0.28, 95% CI: −0.44 to −0.12, P = 0.001). However, there was no significant difference in Cu and Mg levels between COVID-19 patients and controls, severity and non-severity status, and survivors and non-survivors (all P > 0.05). Taken together, COVID-19 patients displayed lower circulating levels of Zn, Fe, and Se, and their levels were associated with severity status. Moreover, circulating Fe levels may provide part of the explanation for the unfavorable survival status. Therefore, we presumed optimistically that supplements of trace elements might provide an adjutant treatment in the early stages of COVID-19.Systematic review registration: [https://www.crd.york.ac.uk/prospero], identifier [CRD42022348599].
- 12 August 2022
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 9, 982032
Open AccessCirculating trace elements status in COVID-19 disease: A meta-analysis
Trace elements are a group of essential metals or metalloids, which are necessary for life, and present in minute amounts. Despite substantial researches highlighting the importance of trace elements in Coronavirus disease 2019 (COVID-19) diseases, a thorough evaluation of the levels of circulating trace elements is lacking. Therefore, we conducted a systematic review and meta-analysis to evaluate the trace element status (Zn, Fe, Cu, Mg, and Se) in COVID-19 disease. We also assessed the relationship between circulating trace elements and COVID-19 disease severity and survival status during follow-up. We searched comprehensively MEDLINE, Web of Science, CNKI, and WangFang databases without language restriction, between November 1, 2019 and April 1, 2022. The search identified 1,566 preliminary references. A total of 49 studies met the eligibility criteria and were included in the review, and 42 studies were included in the final meta-analysis. Meta-analysis showed that COVID-19 patients had significantly lower circulating Zn (SMD: −0.83, 95% CI: −1.19 to −0.46, P < 0.001), Fe (SMD: −1.56, 95% CI: −2.90 to −0.21, P = 0.023), and Se (SMD: −0.75, 95% CI: −0.94 to −0.56, P < 0.001) levels than healthy controls, and circulating Zn (SMD: −0.47, 95% CI: −0.75 to −0.18, P = 0.002), Fe (SMD: −0.45, 95% CI: −0.79 to −0.12, P = 0.008), and Se (SMD: −0.27, 95% CI: −0.49 to −0.04, P = 0.020) levels were associated with the presence of severity status in COVID-19 patients. Moreover, circulating Fe levels in non-survivors were significantly lower than survivors in COVID-19 (SMD: −0.28, 95% CI: −0.44 to −0.12, P = 0.001). However, there was no significant difference in Cu and Mg levels between COVID-19 patients and controls, severity and non-severity status, and survivors and non-survivors (all P > 0.05). Taken together, COVID-19 patients displayed lower circulating levels of Zn, Fe, and Se, and their levels were associated with severity status. Moreover, circulating Fe levels may provide part of the explanation for the unfavorable survival status. Therefore, we presumed optimistically that supplements of trace elements might provide an adjutant treatment in the early stages of COVID-19.Systematic review registration: [https://www.crd.york.ac.uk/prospero], identifier [CRD42022348599].
- Open Access
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 7798654
The Expression and Survival Significance of FOXD1 in Lung Squamous Cell Carcinoma: A Meta‐Analysis, Immunohistochemistry Validation, and Bioinformatics Analysis
Accumulating evidence demonstrated that FOXD1 dysregulation was correlated with a broad spectrum of malignancies. However, litter is known about the role of FOXD1 in the progression of lung squamous cell carcinoma (LUSC). We conducted the comprehensive bioinformatics analysis to investigate FOXD1 expression in LUSC from TCGA and GEO datasets, and validated the FOXD1 expression pattern in clinical samples using immunohistochemistry method. ESTIMATE and CIBERSORT algorithms were performed to assess the relationship of FOXD1 and tumor microenvironment and immune cell infiltration. Our study showed that FOXD1 expression was significantly upregulated in LUSC tissues in TCGA dataset, validated by GEO datasets and clinical samples. In TCGA dataset, Kaplan‐Meier curves showed that high FOXD1 expression was significantly correlated with favorable prognosis in LUSC patients. Moreover, FOXD1 expression has an impact on immune score and the proportions of immune cell infiltration subgroups. Finally, we predicted FOXD1 may be involved in many immune‐related biological functions and cancer‐related signaling pathways. Taken together, FOXD1 was upregulated in LUSC tissues, and FOXD1 expression could be a potential prognostic marker. FOXD1 might be associated with tumor microenvironment and perhaps a potential target in the tumor immunotherapy.
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 7798654
Open AccessThe Expression and Survival Significance of FOXD1 in Lung Squamous Cell Carcinoma: A Meta‐Analysis, Immunohistochemistry Validation, and Bioinformatics Analysis
Accumulating evidence demonstrated that FOXD1 dysregulation was correlated with a broad spectrum of malignancies. However, litter is known about the role of FOXD1 in the progression of lung squamous cell carcinoma (LUSC). We conducted the comprehensive bioinformatics analysis to investigate FOXD1 expression in LUSC from TCGA and GEO datasets, and validated the FOXD1 expression pattern in clinical samples using immunohistochemistry method. ESTIMATE and CIBERSORT algorithms were performed to assess the relationship of FOXD1 and tumor microenvironment and immune cell infiltration. Our study showed that FOXD1 expression was significantly upregulated in LUSC tissues in TCGA dataset, validated by GEO datasets and clinical samples. In TCGA dataset, Kaplan‐Meier curves showed that high FOXD1 expression was significantly correlated with favorable prognosis in LUSC patients. Moreover, FOXD1 expression has an impact on immune score and the proportions of immune cell infiltration subgroups. Finally, we predicted FOXD1 may be involved in many immune‐related biological functions and cancer‐related signaling pathways. Taken together, FOXD1 was upregulated in LUSC tissues, and FOXD1 expression could be a potential prognostic marker. FOXD1 might be associated with tumor microenvironment and perhaps a potential target in the tumor immunotherapy.
- Open Access
- 18 December 2021
- Published by Springer Nature in BMC Gastroenterology
- Vol. 21 (1) , 1-9
Development and validation of a novel diagnostic model for initially clinical diagnosed gastrointestinal stromal tumors using an extreme gradient-boosting machine
Introduction: Gastrointestinal stromal tumor (GIST) is the most common gastrointestinal soft tissue tumor. Clinical diagnosis mainly relies on enhanced CT, endoscopy and endoscopic ultrasound (EUS), but the misdiagnosis rate is still high without fine needle aspiration biopsy. We aim to develop a novel diagnostic model by analyzing the preoperative data of the patients. Methods: We used the data of patients who were initially diagnosed as gastric GIST and underwent partial gastrectomy. The patients were randomly divided into training dataset and test dataset at a ratio of 3 to 1. After pre-experimental screening, max depth = 2, eta = 0.1, gamma = 0.5, and nrounds = 200 were defined as the best parameters, and in this way we developed the initial extreme gradient-boosting (XGBoost) model. Based on the importance of the features in the initial model, we improved the model by excluding the hematological features. In this way we obtained the final XGBoost model and underwent validation using the test dataset. Results: In the initial XGBoost model, we found that the hematological indicators (including inflammation and nutritional indicators) examined before the surgery had little effect on the outcome, so we subsequently excluded the hematological indicators. Similarly, we also screened the features from enhanced CT and ultrasound gastroscopy, and finally determined the 6 most important predictors for GIST diagnosis, including the ratio of long and short diameter under CT, the CT value of the tumor, the enhancement of the tumor in arterial period and venous period, existence of liquid area and calcific area inside the tumor under EUS. Round or round-like tumors with a CT value of around 30 (25–37) and delayed enhancement, as well as liquid but not calcific area inside the tumor best indicate the diagnosis of GIST. Conclusions: We developed a model to further differential diagnose GIST from other tumors in initially clinical diagnosed gastric GIST patients by analyzing the results of clinical examinations that most patients should have completed before surgical resection.
- 18 December 2021
- Published by Springer Nature in BMC Gastroenterology
- Vol. 21 (1) , 1-9
Open AccessDevelopment and validation of a novel diagnostic model for initially clinical diagnosed gastrointestinal stromal tumors using an extreme gradient-boosting machine
Introduction: Gastrointestinal stromal tumor (GIST) is the most common gastrointestinal soft tissue tumor. Clinical diagnosis mainly relies on enhanced CT, endoscopy and endoscopic ultrasound (EUS), but the misdiagnosis rate is still high without fine needle aspiration biopsy. We aim to develop a novel diagnostic model by analyzing the preoperative data of the patients. Methods: We used the data of patients who were initially diagnosed as gastric GIST and underwent partial gastrectomy. The patients were randomly divided into training dataset and test dataset at a ratio of 3 to 1. After pre-experimental screening, max depth = 2, eta = 0.1, gamma = 0.5, and nrounds = 200 were defined as the best parameters, and in this way we developed the initial extreme gradient-boosting (XGBoost) model. Based on the importance of the features in the initial model, we improved the model by excluding the hematological features. In this way we obtained the final XGBoost model and underwent validation using the test dataset. Results: In the initial XGBoost model, we found that the hematological indicators (including inflammation and nutritional indicators) examined before the surgery had little effect on the outcome, so we subsequently excluded the hematological indicators. Similarly, we also screened the features from enhanced CT and ultrasound gastroscopy, and finally determined the 6 most important predictors for GIST diagnosis, including the ratio of long and short diameter under CT, the CT value of the tumor, the enhancement of the tumor in arterial period and venous period, existence of liquid area and calcific area inside the tumor under EUS. Round or round-like tumors with a CT value of around 30 (25–37) and delayed enhancement, as well as liquid but not calcific area inside the tumor best indicate the diagnosis of GIST. Conclusions: We developed a model to further differential diagnose GIST from other tumors in initially clinical diagnosed gastric GIST patients by analyzing the results of clinical examinations that most patients should have completed before surgical resection.
- 27 October 2021
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (36) , 5033-5044
Downregulation of ACE2 is associated with advanced pathological features and poor prognosis in clear cell renal cell carcinoma
Aims: The aim of this study was to explore the alteration in ACE2 expression and correlation between ACE2 expression and immune infiltration in clear cell renal cell carcinoma (ccRCC). Methods: The... Lay abstract To date, the morbidity and mortality of clear cell renal cell carcinoma (ccRCC) are gradually increasing, and ccRCC is more aggressive than other kidney cancer types. The ACE2 protein ...
- 27 October 2021
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (36) , 5033-5044
Downregulation of ACE2 is associated with advanced pathological features and poor prognosis in clear cell renal cell carcinoma
Aims: The aim of this study was to explore the alteration in ACE2 expression and correlation between ACE2 expression and immune infiltration in clear cell renal cell carcinoma (ccRCC). Methods: The... Lay abstract To date, the morbidity and mortality of clear cell renal cell carcinoma (ccRCC) are gradually increasing, and ccRCC is more aggressive than other kidney cancer types. The ACE2 protein ...
- Open Access
- 28 July 2021
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 41 (7)
FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis
Forkhead box D1 (FOXD1) is a new member of FOX transcription factor family. FOXD1 has demonstrated multilevel roles during normal development, and several diseases’ pathogenesis. However, little is known about the role of FOXD1 in the progression of head and neck squamous cancer (HNSC). In the present study, we analyzed FOXD1 expression pattern using The Cancer Genome Atlas (TCGA) dataset, Gene Expression Omnibus (GEO) datasets, HNSC cell lines, and HNSC tissues. Then, we analyzed the correlation between FOXD1 expression and clinical characteristics, and evaluated the prognostic value of FOXD1 in HNSC. Moreover, we assessed the relationship between FOXD1 expression and tumor microenvironment (TME) and immune cell infiltration using Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) and Cell-type Identification By Estimating Relative Subsets Of known RNA Transcripts (CIBERSORT) algorithms. Finally, we predicted the FOXD1-related biological processes (BPs) and signal pathways. FOXD1 was up-regulated in HNSC tissues in TCGA datasets, validated by GEO datasets, HNSC cell lines and HNSC tissues. FOXD1 expression was significantly associated with tumor site and HPV infection. Univariate and multivariate Cox regression analyses showed that FOXD1 expression was an independent prognostic factor. Moreover, we found that the proportions of naïve B cells, plasma cells, and resting dendritic cells (DCs) were negatively correlated with FOXD1 expression, otherwise, the proportion of activated mast cells was positively correlated with FOXD1 expression using CIBERSORT algorithm. Gene Set Enrichment Analyses (GSEAs) revealed that FOXD1 was mainly involved in cancer-related signaling pathway and metabolism-related pathways. FOXD1 was a potential oncogene, and might represent an indicator for predicting overall survival (OS) of HNSC patients. Moreover, many cancer-related pathways and metabolism-related processes may be regulated by FOXD1.
- 28 July 2021
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 41 (7)
Open AccessFOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis
Forkhead box D1 (FOXD1) is a new member of FOX transcription factor family. FOXD1 has demonstrated multilevel roles during normal development, and several diseases’ pathogenesis. However, little is known about the role of FOXD1 in the progression of head and neck squamous cancer (HNSC). In the present study, we analyzed FOXD1 expression pattern using The Cancer Genome Atlas (TCGA) dataset, Gene Expression Omnibus (GEO) datasets, HNSC cell lines, and HNSC tissues. Then, we analyzed the correlation between FOXD1 expression and clinical characteristics, and evaluated the prognostic value of FOXD1 in HNSC. Moreover, we assessed the relationship between FOXD1 expression and tumor microenvironment (TME) and immune cell infiltration using Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) and Cell-type Identification By Estimating Relative Subsets Of known RNA Transcripts (CIBERSORT) algorithms. Finally, we predicted the FOXD1-related biological processes (BPs) and signal pathways. FOXD1 was up-regulated in HNSC tissues in TCGA datasets, validated by GEO datasets, HNSC cell lines and HNSC tissues. FOXD1 expression was significantly associated with tumor site and HPV infection. Univariate and multivariate Cox regression analyses showed that FOXD1 expression was an independent prognostic factor. Moreover, we found that the proportions of naïve B cells, plasma cells, and resting dendritic cells (DCs) were negatively correlated with FOXD1 expression, otherwise, the proportion of activated mast cells was positively correlated with FOXD1 expression using CIBERSORT algorithm. Gene Set Enrichment Analyses (GSEAs) revealed that FOXD1 was mainly involved in cancer-related signaling pathway and metabolism-related pathways. FOXD1 was a potential oncogene, and might represent an indicator for predicting overall survival (OS) of HNSC patients. Moreover, many cancer-related pathways and metabolism-related processes may be regulated by FOXD1.
- Open Access
- 13 October 2020
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 40 (10)
Identification of prognosis-related genes in the tumor microenvironment of stomach adenocarcinoma by TCGA and GEO datasets
Accumulating evidence has demonstrated that tumor microenvironment (TME) plays a crucial role in stomach adenocarcinoma (STAD) development, progression, prognosis and immunotherapeutic responses. How the genes in TME interact and behave is extremely crucial for tumor investigation. In the present study, we used gene expression data of STAD available from TCGA and GEO datasets to infer tumor purity using ESTIMATE algorithms, and predicted the associations between tumor purity and clinical features and clinical outcomes. Next, we calculated the differentially expressed genes (DEGs) from the comparisons of immune and stromal scores, and postulated key biological processes and pathways that the DEGs mainly involved in. Then, we analyzed the prognostic values of DEGs in TCGA dataset, and validated the results by GEO dataset. Finally, we used CIBERSORT computational algorithm to estimate the 22 tumor infiltrating immune cells (TIICs) subsets in STAD tissues. We found that stromal and immune scores were significantly correlated with STAD subtypes, clinical stages, Helicobacter polyri infection, and stromal scores could predict the clinical outcomes in STAD patients. Moreover, we screened 307 common DEGs in TCGA and GSE51105 datasets. In the prognosis analyses, we only found OGN, JAM2, RERG, OLFML2B, and ADAMTS1 genes were significantly associated with overall survival in TCGA and GSE84437 datasets, and these genes were correlated with the fractions of T cells, B cells, macrophages, monocytes, NK cells and DC cells, respectively. Our comprehensive analyses for transcriptional data not only improved the understanding of characteristics of TME, but also provided the targets for individual therapy in STAD.
- 13 October 2020
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 40 (10)
Open AccessIdentification of prognosis-related genes in the tumor microenvironment of stomach adenocarcinoma by TCGA and GEO datasets
Accumulating evidence has demonstrated that tumor microenvironment (TME) plays a crucial role in stomach adenocarcinoma (STAD) development, progression, prognosis and immunotherapeutic responses. How the genes in TME interact and behave is extremely crucial for tumor investigation. In the present study, we used gene expression data of STAD available from TCGA and GEO datasets to infer tumor purity using ESTIMATE algorithms, and predicted the associations between tumor purity and clinical features and clinical outcomes. Next, we calculated the differentially expressed genes (DEGs) from the comparisons of immune and stromal scores, and postulated key biological processes and pathways that the DEGs mainly involved in. Then, we analyzed the prognostic values of DEGs in TCGA dataset, and validated the results by GEO dataset. Finally, we used CIBERSORT computational algorithm to estimate the 22 tumor infiltrating immune cells (TIICs) subsets in STAD tissues. We found that stromal and immune scores were significantly correlated with STAD subtypes, clinical stages, Helicobacter polyri infection, and stromal scores could predict the clinical outcomes in STAD patients. Moreover, we screened 307 common DEGs in TCGA and GSE51105 datasets. In the prognosis analyses, we only found OGN, JAM2, RERG, OLFML2B, and ADAMTS1 genes were significantly associated with overall survival in TCGA and GSE84437 datasets, and these genes were correlated with the fractions of T cells, B cells, macrophages, monocytes, NK cells and DC cells, respectively. Our comprehensive analyses for transcriptional data not only improved the understanding of characteristics of TME, but also provided the targets for individual therapy in STAD.
- 5 June 2020
- Published by Taylor & Francis in Future Oncology
- Vol. 16 (24) , 1825-1837
Comprehensive analysis of microenvironment-related genes in lung adenocarcinoma
Aim: Understanding the cell types and cell compositions in tumor environment (TME) and the gene changes in lung adenocarcinoma (LUAD) may provide insights on immune profiles and treatment targets for LUAD patients. Materials & methods: The RNA-Seq data from The Cancer Genome Atlas database were used to calculate the stromal scores and immune scores and analyzed the fractions of tumor infiltrating immune cells in LUAD samples with ESTIMATE and CIBERSORT algorithm. Results: We extracted a list of TME-related differentially expressed genes and performed the functional enrichment analysis. We found these genes were mainly enriched in immune response and cancer-related signal pathways. The prognosis analysis indicated that LINC00211, MUC2, LINC00426, LY86-AS1 ZEB2-AS1 and EREG were associated with prognosis in LUAD patients. Conclusion: The current study provides novel insights into immune files and gene changes in TME in LUAD patients.
- 5 June 2020
- Published by Taylor & Francis in Future Oncology
- Vol. 16 (24) , 1825-1837
Comprehensive analysis of microenvironment-related genes in lung adenocarcinoma
Aim: Understanding the cell types and cell compositions in tumor environment (TME) and the gene changes in lung adenocarcinoma (LUAD) may provide insights on immune profiles and treatment targets for LUAD patients. Materials & methods: The RNA-Seq data from The Cancer Genome Atlas database were used to calculate the stromal scores and immune scores and analyzed the fractions of tumor infiltrating immune cells in LUAD samples with ESTIMATE and CIBERSORT algorithm. Results: We extracted a list of TME-related differentially expressed genes and performed the functional enrichment analysis. We found these genes were mainly enriched in immune response and cancer-related signal pathways. The prognosis analysis indicated that LINC00211, MUC2, LINC00426, LY86-AS1 ZEB2-AS1 and EREG were associated with prognosis in LUAD patients. Conclusion: The current study provides novel insights into immune files and gene changes in TME in LUAD patients.
- 1 June 2020
- Published by Elsevier in Pathology - Research and Practice
- Vol. 216 (6) , 152943
PTEN mutation: A potential prognostic factor associated with immune infiltration in endometrial carcinoma
- 1 June 2020
- Published by Elsevier in Pathology - Research and Practice
- Vol. 216 (6) , 152943
PTEN mutation: A potential prognostic factor associated with immune infiltration in endometrial carcinoma